| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8819927 | Respiratory Medicine | 2018 | 7 Pages |
Abstract
Infliximab biosimilar Inflectra® seems effective in the treatment of refractory sarcoidosis with a comparable safety profile to the reference product Remicade®. Inflectra® can be considered as an alternative and less expensive option for patients with refractory sarcoidosis.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Milou C. Schimmelpennink, Adriane D.M. Vorselaars, Frouke T. van Beek, Heleen A. Crommelin, Vera H.M. Deneer, Ruth G.M. Keijsers, Marcel Veltkamp,